The auction, overseen by boutique investment bank Houlihan Lokey, began in early 2025 and drew interest from several of the world's largest buyout houses, including Blackstone, EQT and TPG, according to the same report. The shortlist was narrowed to Bain and Blackstone before Vitabiotics entered exclusive talks with Bain last month. EQT and TPG dropped away as the price tag firmed up close to £1 billion.

Insiders cautioned that talks remain "delicately placed" and there is still a risk the transaction slips or unravels, as first reported by Business Matters. A deal could be announced as early as this week. Bain Capital declined to comment. Vitabiotics had been approached for comment.

What the £900 million price tag implies about the supplements sector

At roughly 4.5 times claimed annual sales of £195.6 million, the reported valuation is a punchy multiple for a privately held consumer-health business. It reflects two things: the defensive, repeat-purchase cash flows that supplements generate, and the broader willingness of buyout houses to pay up for resilient UK consumer brands even in uncertain macroeconomic conditions.

The deal sits within a visible wave of PE and trade buyers targeting functional nutrition. Danone completed a €1 billion acquisition of Huel earlier this year, as reported by Business Matters. Bain Capital itself has been ploughing capital into the wellness space, including its 2023 acquisition of US sports-nutrition group 1440 Foods and a stake in India's Emcure Pharmaceuticals.

For operators in adjacent categories, the multiple is instructive. A 4.5-times-sales tag is not typical for a mid-market consumer brand; it signals that buyers are pricing in both international distribution (Vitabiotics claims pharmacy-shelf presence in more than 100 countries) and the structural tailwind of post-pandemic spending on preventive health. Whether the multiple holds up to scrutiny depends, in part, on how much financial detail Bain has been able to verify during due diligence.

From forklift to founder exit: the Lalvani ownership timeline

Kartar Lalvani founded Vitabiotics in 1971. The company built a portfolio of pharmacy-counter brands, including Wellman, Wellwoman, Perfectil, Pregnacare and Menopace, that became fixtures of the UK high street. Celebrity ambassadors such as Tess Daly, David Gandy and Davina McCall fronted campaigns over the years.

Tej Lalvani, Kartar's son, joined the business after university, starting on the warehouse floor driving a forklift, according to Business Matters. He worked his way through operations before taking charge in 2015. Under his leadership, annual global sales are said to have almost doubled from £101 million to £195.6 million.

Lalvani raised his public profile further by joining the BBC's Dragons' Den panel in 2017, staying for four series and backing businesses ranging from herbal tea brands to protein shake bottles. The Lalvani family is ranked 255th on The Sunday Times Rich List, with an estimated fortune of £525 million.

The arc, from immigrant founder to second-generation operator to near-billion-pound exit, is a textbook case of patient brand-building. But the timeline also reveals a strategic choice: the family waited until the supplements market was attracting peak PE interest before running a formal auction, maximising competitive tension among bidders.

Bain Capital's UK track record and the LV= shadow

Bain Capital's last high-profile UK transaction was considerably less smooth. In 2021, its £530 million bid for mutual insurer LV= was rejected by the insurer's members in a vote that drew political scrutiny and tabloid headlines. The episode damaged the firm's standing among UK boards and policymakers.

Since then, Bain has worked to rebuild its reputation in the British market. A clean acquisition of a well-regarded family brand like Vitabiotics would serve that purpose. According to reports in the Financial Times, the deal would rank among the largest sponsor-led acquisitions of a UK family-owned consumer business this year.

The contrast between the two transactions is worth noting. LV= was a member-owned mutual; its stakeholders had a direct democratic veto. Vitabiotics is a private, family-controlled business. There is no membership vote to navigate, no regulator with a specific mandate over the buyer's identity. The path to completion is structurally simpler, provided the commercial terms hold.

The BVI question

One complication is transparency. Vitabiotics Group Holdings, the parent entity, is registered in the British Virgin Islands, an arrangement that allows the company to keep the finer points of its financial performance out of public view. The claimed sales figure of £195.6 million cannot be independently verified through UK filings.

For Bain, this is a due-diligence problem rather than a deal-breaker; PE firms routinely underwrite acquisitions on the basis of vendor data rooms and management accounts. For outside observers, the BVI structure is a reminder that headline valuations attached to private businesses rest on numbers that only the parties to the transaction can fully interrogate.

Lessons for family-owned businesses weighing a PE sale

The Vitabiotics process offers several practical takeaways for founders and family operators considering an exit.

Timing matters more than urgency. The Lalvani family ran the business for more than half a century before engaging advisers. They launched the auction when PE appetite for consumer-health assets was at a cyclical high, not when they needed liquidity.

Competitive tension drives price. By attracting interest from Bain, Blackstone, EQT and TPG, Houlihan Lokey created an environment in which bidders competed upward. The final price, roughly 4.5 times sales, is well above the two-to-three-times range common in mid-market consumer deals.

Brand recognition is a valuation lever. Vitabiotics' pharmacy presence, celebrity endorsements and consumer trust gave bidders confidence in revenue durability. Functional assets, such as factories or supply contracts, matter less in a branded supplements business than shelf space and consumer recall.

Offshore structures create trade-offs. The BVI holding entity may have offered tax efficiency and privacy during the family-ownership period. In a sale process, it introduces friction: buyers must spend more time verifying financials, and the lack of public accounts invites scepticism about the headline numbers. Founders should weigh the long-term cost of opacity against its near-term benefits.

Post-deal involvement is negotiable. According to Business Matters, Bain is expected to retain the operational team, and Lalvani is likely to remain involved through a transition period. For founders emotionally attached to their businesses, a structured earn-out or advisory role can ease the psychological weight of a full exit.

Whether the deal closes at the reported price, or at all, remains to be seen. But the process itself, a 55-year build, a competitive auction and a near-billion-pound price tag, is already a reference point for every UK family business weighing its options.